FIGURE 1.
Primary CV outcome in once‐weekly GLP‐1 RA CVOTs. *P ≤ .05 for significance; †3‐point MACE: CV death, non‐fatal MI or non‐fatal stroke; ‡ post hoc analysis. CI, confidence interval; CV, cardiovascular; CVOT, cardiovascular outcomes trial; ER, extended release; GLP‐1 RAs, glucagon‐like peptide‐1 receptor agonists; HR, hazard ratio; MACE, major adverse cardiovascular events; n, number of patients with events; N, number of patients in each treatment group